Walleye Capital LLC Increases Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

Walleye Capital LLC increased its position in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) by 59.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 220,142 shares of the biotechnology company's stock after purchasing an additional 81,739 shares during the period. Walleye Capital LLC owned 0.24% of Rocket Pharmaceuticals worth $2,767,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Covestor Ltd lifted its position in Rocket Pharmaceuticals by 33,166.7% during the 4th quarter. Covestor Ltd now owns 1,996 shares of the biotechnology company's stock valued at $25,000 after acquiring an additional 1,990 shares during the period. Signaturefd LLC increased its stake in shares of Rocket Pharmaceuticals by 319.8% during the fourth quarter. Signaturefd LLC now owns 4,916 shares of the biotechnology company's stock valued at $62,000 after purchasing an additional 3,745 shares in the last quarter. Harbour Investments Inc. boosted its position in shares of Rocket Pharmaceuticals by 51.9% in the 4th quarter. Harbour Investments Inc. now owns 5,385 shares of the biotechnology company's stock worth $68,000 after purchasing an additional 1,840 shares in the last quarter. KBC Group NV boosted its position in shares of Rocket Pharmaceuticals by 159.6% in the 4th quarter. KBC Group NV now owns 5,475 shares of the biotechnology company's stock worth $69,000 after purchasing an additional 3,366 shares in the last quarter. Finally, E Fund Management Co. Ltd. bought a new stake in shares of Rocket Pharmaceuticals in the 4th quarter worth approximately $139,000. Institutional investors own 98.39% of the company's stock.

Analyst Upgrades and Downgrades

RCKT has been the topic of several analyst reports. Needham & Company LLC reissued a "buy" rating and issued a $42.00 target price on shares of Rocket Pharmaceuticals in a report on Wednesday, April 9th. Scotiabank increased their price objective on shares of Rocket Pharmaceuticals from $51.00 to $52.00 and gave the company a "sector outperform" rating in a research report on Monday, March 3rd. Canaccord Genuity Group reduced their price objective on shares of Rocket Pharmaceuticals from $39.00 to $36.00 and set a "buy" rating for the company in a research note on Monday, March 3rd. The Goldman Sachs Group dropped their target price on shares of Rocket Pharmaceuticals from $29.00 to $15.00 and set a "neutral" rating on the stock in a research note on Monday, March 3rd. Finally, Chardan Capital decreased their price objective on shares of Rocket Pharmaceuticals from $62.00 to $54.00 and set a "buy" rating for the company in a report on Friday, February 28th. One research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $43.00.

Insider Transactions at Rocket Pharmaceuticals

In related news, insider Kinnari Patel purchased 21,099 shares of Rocket Pharmaceuticals stock in a transaction on Wednesday, April 9th. The stock was acquired at an average price of $4.70 per share, for a total transaction of $99,165.30. Following the completion of the transaction, the insider now directly owns 26,774 shares in the company, valued at $125,837.80. This represents a 371.79 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Aaron Ondrey sold 7,489 shares of the firm's stock in a transaction dated Friday, April 4th. The stock was sold at an average price of $5.29, for a total value of $39,616.81. Following the completion of the transaction, the chief financial officer now directly owns 129,650 shares in the company, valued at $685,848.50. This trade represents a 5.46 % decrease in their position. The disclosure for this sale can be found here. 28.50% of the stock is currently owned by company insiders.

Rocket Pharmaceuticals Stock Performance

Shares of NASDAQ:RCKT traded up $0.14 during trading on Wednesday, hitting $7.11. The company's stock had a trading volume of 1,315,408 shares, compared to its average volume of 1,307,721. The company has a debt-to-equity ratio of 0.06, a current ratio of 6.05 and a quick ratio of 6.05. The firm has a market cap of $758.14 million, a price-to-earnings ratio of -2.59 and a beta of 1.00. The company has a 50-day moving average of $7.84 and a 200-day moving average of $11.56. Rocket Pharmaceuticals, Inc. has a 12 month low of $4.55 and a 12 month high of $26.98.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last announced its earnings results on Monday, March 3rd. The biotechnology company reported ($0.62) EPS for the quarter, beating analysts' consensus estimates of ($0.68) by $0.06. On average, sell-side analysts expect that Rocket Pharmaceuticals, Inc. will post -2.83 earnings per share for the current year.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.